NO20045304L - Fremgangsmate for regulert hyperstimulering av eggstokk, samt kitt for anvendelse i samme - Google Patents
Fremgangsmate for regulert hyperstimulering av eggstokk, samt kitt for anvendelse i sammeInfo
- Publication number
- NO20045304L NO20045304L NO20045304A NO20045304A NO20045304L NO 20045304 L NO20045304 L NO 20045304L NO 20045304 A NO20045304 A NO 20045304A NO 20045304 A NO20045304 A NO 20045304A NO 20045304 L NO20045304 L NO 20045304L
- Authority
- NO
- Norway
- Prior art keywords
- substance
- administration
- fsh
- amount equivalent
- unit containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Et aspekt av foreliggende oppfinnelse vedrører en fremgangsmåte for regulert hyperstimulering av eggstokk i et hunnkjønn pattedyr, hvor fremgangsmåten omfatter samadministrering til nevnte hunnkjønn, en substans som har follikelstimulerende aktivitet (FSH-substans) i en mengde effektiv til å stimulere multippel folikkulær utvikling; gonadotropinfrigjørende hormon (GnRH) antagonist i en mengde ekvivalent til en daglig subkutanøs dosering av minst 0,5 mg ganirelix for å hindre en prematur LH-bølge; og en LH-substans i en mengde effektiv til å hindre eller undertrykke symptomer av luteiniserende hormon (LH) mangel resulterende for administreringen av GnRH-antagonisten; etterfulgt av administrering av en meiose- og luteiniseringsinduserende substans (ML-substans) i en mengde effektiv til å stimulere gjenopptakelse av meiose og luteinisering, og hvor LH-substansen ikke er opptatt fra urinen til kvinner. Et annet aspekt ved foreliggende oppfinnelse vedrører et farmasøytisk kitt for anvendelse i en fremgangsmåte for regulert hyperstimulering, hvor kittet omfatte r: minst en parenteral eller oral doseringsenhet inneholdende en eller flere FSH-substanser i en mengde ekvivalent til en subkutanøs dosering av 50-1500 I.U. FSH; minst en parenteral doseringsenhet inneholdende en eller flere GnRH-antagonister i en mengde ekvivalent til en subkutanøs dosering av 0,5-25 mg ganirelix; minst en parenteral doseringsenhet inneholdende en eller flere LH-substanser i en mengde ekvivalent til en subkutanøs dosering av 50-3000 I.U. rekombinant LIHI; hvor LH-substansen ikke er opptatt fra urin fra kvinner.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077221 | 2002-06-07 | ||
| PCT/NL2003/000370 WO2003103770A2 (en) | 2002-06-07 | 2003-06-06 | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045304L true NO20045304L (no) | 2005-02-07 |
Family
ID=29724462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045304A NO20045304L (no) | 2002-06-07 | 2004-12-03 | Fremgangsmate for regulert hyperstimulering av eggstokk, samt kitt for anvendelse i samme |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7815912B2 (no) |
| EP (1) | EP1511537B1 (no) |
| JP (1) | JP2005530818A (no) |
| KR (1) | KR20050058285A (no) |
| CN (1) | CN1684737A (no) |
| AU (1) | AU2003274929B2 (no) |
| BR (1) | BR0305033A (no) |
| CA (1) | CA2488719A1 (no) |
| EA (1) | EA009371B1 (no) |
| ES (1) | ES2399962T3 (no) |
| IL (1) | IL165522A0 (no) |
| IS (1) | IS7586A (no) |
| ME (1) | MEP39308A (no) |
| MX (1) | MXPA04012246A (no) |
| NO (1) | NO20045304L (no) |
| NZ (1) | NZ536984A (no) |
| PL (1) | PL373991A1 (no) |
| RS (1) | RS105004A (no) |
| UA (1) | UA81251C2 (no) |
| WO (1) | WO2003103770A2 (no) |
| ZA (1) | ZA200409857B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2114412B1 (en) * | 2007-01-08 | 2010-07-14 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
| KR20140053991A (ko) * | 2011-07-18 | 2014-05-08 | 아츠 바이올로직스 에이/에스 | 장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물 |
| US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
| US9282995B2 (en) * | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| ES2898778T3 (es) | 2016-07-21 | 2022-03-08 | ObsEva SA | Pautas posológicas de antagonistas de oxitocina para promover la implantación de embriones y prevenir aborto espontáneo |
| CA3149898A1 (en) | 2019-09-03 | 2021-03-11 | Ernest Loumaye | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| CN115380122A (zh) | 2020-02-10 | 2022-11-22 | 奥布赛瓦股份公司 | 用于催产素受体拮抗剂疗法的生物标志物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0788799A3 (en) * | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| CN1199642A (zh) * | 1997-05-16 | 1998-11-25 | Asta药物股份公司 | 治疗不育症的lhrh－拮抗剂 |
| ATE302018T1 (de) * | 1997-06-20 | 2005-09-15 | Akzo Nobel Nv | Gonadotropin releasing hormon antagonist |
| KR100632722B1 (ko) * | 1998-04-23 | 2006-10-16 | 젠타리스 게엠베하 | 불임증 치료용 약제학적 제제 |
| AU2794100A (en) * | 1999-02-24 | 2000-09-14 | Novo Nordisk A/S | Treatment of infertility |
| US20030092628A1 (en) * | 1999-06-23 | 2003-05-15 | De Greef Henrik Johan Matthieu Maria | Gonadotropin releasing hormone antagonist |
| WO2001000227A1 (en) * | 1999-06-23 | 2001-01-04 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
| JP2005504072A (ja) * | 2001-09-12 | 2005-02-10 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 過排卵誘起におけるｌｈの使用 |
| DE60223284T2 (de) | 2001-12-21 | 2008-07-31 | Pantarhei Bioscience B.V. | Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutischen kit zur verwendung in diesem verfahren |
-
2003
- 2003-06-06 CN CNA038183900A patent/CN1684737A/zh active Pending
- 2003-06-06 ES ES03741621T patent/ES2399962T3/es not_active Expired - Lifetime
- 2003-06-06 RS YUP-1050/04A patent/RS105004A/sr unknown
- 2003-06-06 NZ NZ536984A patent/NZ536984A/en unknown
- 2003-06-06 EP EP03741621A patent/EP1511537B1/en not_active Expired - Lifetime
- 2003-06-06 JP JP2004510888A patent/JP2005530818A/ja active Pending
- 2003-06-06 KR KR1020047019890A patent/KR20050058285A/ko not_active Application Discontinuation
- 2003-06-06 CA CA002488719A patent/CA2488719A1/en not_active Abandoned
- 2003-06-06 AU AU2003274929A patent/AU2003274929B2/en not_active Ceased
- 2003-06-06 BR BR0305033-5A patent/BR0305033A/pt not_active IP Right Cessation
- 2003-06-06 EA EA200401619A patent/EA009371B1/ru not_active IP Right Cessation
- 2003-06-06 US US10/517,028 patent/US7815912B2/en not_active Expired - Fee Related
- 2003-06-06 UA UAA200500168A patent/UA81251C2/uk unknown
- 2003-06-06 MX MXPA04012246A patent/MXPA04012246A/es unknown
- 2003-06-06 WO PCT/NL2003/000370 patent/WO2003103770A2/en active Application Filing
- 2003-06-06 PL PL03373991A patent/PL373991A1/xx not_active Application Discontinuation
- 2003-06-06 ME MEP-393/08A patent/MEP39308A/xx unknown
-
2004
- 2004-12-02 IL IL16552204A patent/IL165522A0/xx unknown
- 2004-12-03 NO NO20045304A patent/NO20045304L/no not_active Application Discontinuation
- 2004-12-03 IS IS7586A patent/IS7586A/is unknown
- 2004-12-06 ZA ZA200409857A patent/ZA200409857B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IS7586A (is) | 2004-12-03 |
| AU2003274929A1 (en) | 2003-12-22 |
| CA2488719A1 (en) | 2003-12-18 |
| EP1511537B1 (en) | 2012-11-21 |
| NZ536984A (en) | 2008-01-31 |
| EP1511537A2 (en) | 2005-03-09 |
| UA81251C2 (en) | 2007-12-25 |
| AU2003274929B2 (en) | 2008-04-10 |
| IL165522A0 (en) | 2006-01-15 |
| RS105004A (en) | 2007-02-05 |
| CN1684737A (zh) | 2005-10-19 |
| ES2399962T3 (es) | 2013-04-04 |
| PL373991A1 (en) | 2005-09-19 |
| EA200401619A1 (ru) | 2005-06-30 |
| US20050235374A1 (en) | 2005-10-20 |
| BR0305033A (pt) | 2004-11-09 |
| MXPA04012246A (es) | 2005-04-08 |
| WO2003103770A3 (en) | 2004-04-22 |
| MEP39308A (en) | 2011-02-10 |
| EA009371B1 (ru) | 2007-12-28 |
| ZA200409857B (en) | 2006-02-22 |
| KR20050058285A (ko) | 2005-06-16 |
| JP2005530818A (ja) | 2005-10-13 |
| US7815912B2 (en) | 2010-10-19 |
| WO2003103770A2 (en) | 2003-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pierroz et al. | Chronic administration of neuropeptide Y into the lateral ventricle starting at 30 days of life delays sexual maturation in the female rat | |
| Schally et al. | LH‐RH agonists and antagonists | |
| Ayalon et al. | Acute Effect of▵ 1–Tetrahydrocannabinol on the Hypothalamo-Pituitary-Ovarian Axis in the Rat | |
| Sharoni et al. | Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. | |
| Lin et al. | Effects of [d-Arg6, Trp7, Leu8, Pro9 NEt]-luteinizing hormone-releasing hormone (sGnRH-A) and [d-Ala6, Pro9NEt]-luteinizing hormone-releasing hormone (LHRH-A), in combination with pimozide or domperidone, on Gonadotropin release and ovulation in the Chinese loach and common carp | |
| DE69927705T2 (de) | Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen-gonadenachse | |
| AU2002310788B2 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| NO20045304L (no) | Fremgangsmate for regulert hyperstimulering av eggstokk, samt kitt for anvendelse i samme | |
| Corbin et al. | Peptide Contraception: Antifertility Properties of LH‐RH Analogues | |
| Neidhart | Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion | |
| Volkmann et al. | Failure of hCG to support luteal function in bitches after estrus induction using deslorelin implants | |
| LIU et al. | Synthesis and release of luteinizing hormone in vitro by rat anterior pituitary cells: effects of gallopamil hydrochloride (D600) and pimozide | |
| RU2181598C2 (ru) | Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения | |
| Ruzsas et al. | Role of serotoninergic neurones in the control of gonadotrophin and prolactin secretion in the rat | |
| Yen | Gonadotropin-releasing hormone | |
| Kasting et al. | Endogenous prostaglandins affect growth hormone and thyrotropin release at a hypothalamic, not a pituitary level | |
| US20210137923A1 (en) | Treatment of sexual dysfunction | |
| US20120004182A1 (en) | Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells | |
| CA2472309A1 (en) | Multiple dose aromatase inhibitor for treating infertility | |
| KR20030051828A (ko) | 에스트로겐 의존성 질환의 병용 치료법 | |
| CA2444980A1 (en) | Single dose aromatase inhibitor for treating infertility | |
| Smythe et al. | Acute effects of lithium on central dopamine and serotonin activity reflected by inhibition of prolactin and growth hormone secretion in the rat | |
| And et al. | Effects of oral and intravenous TRH and metoclopramide on PRL and TSH secretion in women | |
| Krieg, Jr et al. | Differential time-and dose-dependent effects in the haloperidol blockade of luteinizing hormone release and ovulation | |
| Aragona et al. | IVF in poor responder patients: a controlled trial between natural cycle and micro-dose GnRH analogue flare |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |